Liraglutide,a glucagon-like peptide-1 analog,increased insulin sensitivity assessed by hyperinsulinemic-euglycemic clamp examination in patients with uncontrolled type 2 diabetes mellitus

Aims. glucagon-like peptide-1 (glp-1) analog promotes insulin secretion by acting on pancreatic β-cells. this antihyperglycemic treatment for type 2 diabetes mellitus (dm) has attracted increased clinical attention not only for its antihyperglycemic action but also for its potential extrapancreatic effects. we investigated whether liraglutide,a glp-1 analog,could enhance insulin sensitivity as assessed by the hyperinsulinemic-euglycemic clamp in type 2 dm patients. materials. we prospectively enrolled 31 uncontrolled type 2 dm patients who were hospitalized and equally managed by guided diet- and exercise-therapies and then introduced to either liraglutide- or intensive insulin-therapy for 4 weeks. insulin sensitivity was assessed by the glucose infusion rate (gir) using hyperinsulinemic-euglycemic clamp before and after the therapies. results. values of hba1c,postprandial plasma glucose,and body mass index (bmi) were significantly decreased by hospitalized intensive insulin-therapy or liraglutide-therapy. gir was significantly increased by liraglutide-therapy but not by insulin-therapy,indicating that liraglutide-therapy significantly enhanced insulin sensitivity. bmi decreased during liraglutide-therapy but was not significantly correlated with changes in gir. multivariate logistic regression analysis demonstrated that liraglutide-therapy significantly correlated with increased insulin sensitivity in uncontrolled dm patients. conclusions. liraglutide may exhibit favorable effects on diabetes control for type 2 dm patients by increasing insulin sensitivity as an extrapancreatic action. clinical trial registration unique identifier is umin000015201. copyright © 2015 hideaki jinnouchi et al.